<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01668823</url>
  </required_header>
  <id_info>
    <org_study_id>I 05903</org_study_id>
    <secondary_id>NCI-2010-02114</secondary_id>
    <nct_id>NCT01668823</nct_id>
  </id_info>
  <brief_title>Photodynamic Therapy in Treating Patients With Lung Cancer</brief_title>
  <official_title>A Phase I Study of Light Dose for Photodynamic Therapy(PDT) Using 2-[ 1-hexyloxyethel]-2-devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-small Cell Carcinoma in Situ or Non-small Cell Microinvasive Carcinoma. A Dose Ranging Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of photodynamic therapy using&#xD;
      HPPH in treating patients with lung cancer. Photodynamic therapy uses a drug, such as HPPH,&#xD;
      that becomes active when it is exposed to a certain kind of light. When the drug is active,&#xD;
      cancer cells are killed.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine maximally tolerated light dose (MTID). Identify systemic and normal tissue&#xD;
      toxicity using 2-[hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) for photodynamic therapy&#xD;
      in patients with bronchogenic carcinoma-in-situ (CIS) or microinvasive carcinoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To study tumor response in patients with bronchogenic carcinoma-in-situ (CIS) or&#xD;
      bronchogenic microinvasive carcinoma.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive HPPH intravenously (IV) over 1 hour on day 1. Patients then photodynamic&#xD;
      therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for&#xD;
      endoscopic debridement on day 5.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 4-6 weeks, 6 months, and&#xD;
      then periodically for at least 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2004</start_date>
  <completion_date>June 2014</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>MTID</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Defined as the dose at which =&lt; 1 out of 6 patients experiences dose-limiting toxicity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic toxicity according to NCI Common Toxicity Criteria version 2</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>PDT-related normal tissue toxicity</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Assessed by a scale with grades 0-3 being acceptable, grade 4 being unacceptable, and grade 5 being stopping study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>Up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Adenocarcinoma of the Lung</condition>
  <condition>Large Cell Lung Cancer</condition>
  <condition>Recurrent Non-small Cell Lung Cancer</condition>
  <condition>Squamous Cell Lung Cancer</condition>
  <condition>Stage 0 Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (PDT using HPPH)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive HPPH IV over 1 hour on day 1. Patients then photodynamic therapy with laser light on day 3. Patients also undergo therapeutic bronchoscopy for endoscopic debridement on day 5.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HPPH</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (PDT using HPPH)</arm_group_label>
    <other_name>Photochlor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>photodynamic therapy</intervention_name>
    <description>Undergo photodynamic therapy with HPPH</description>
    <arm_group_label>Treatment (PDT using HPPH)</arm_group_label>
    <other_name>Light Infusion Therapyâ„¢</other_name>
    <other_name>PDT</other_name>
    <other_name>therapy, photodynamic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic bronchoscopy</intervention_name>
    <description>Undergo therapeutic bronchoscopy for endoscopic debridement</description>
    <arm_group_label>Treatment (PDT using HPPH)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with biopsy confirmed carcinoma-in-situ (CIS) or microinvasive lung cancer&#xD;
&#xD;
          -  Patients may have squamous cell carcinoma, adenocarcinoma, or large cell carcinoma&#xD;
&#xD;
          -  Patients may have received prior therapy for lung cancer of any type, e.g.&#xD;
             chemotherapy, radiation therapy&#xD;
&#xD;
          -  Patients must have no contraindications for bronchoscopy&#xD;
&#xD;
          -  Female patients must not be pregnant and must be practicing a medically acceptable&#xD;
             form of birth control, be sterile or post-menopausal&#xD;
&#xD;
          -  Patients must have a Karnofsky scale 50 or above (Eastern Cooperative Oncology Group&#xD;
             [ECOG] 0-2)&#xD;
&#xD;
          -  Patients must sign an Informed Consent according to Food and Drug Administration (FDA)&#xD;
             guidelines acceptable to the Roswell Park Cancer Institute (RPCI) Institutional Review&#xD;
             Board (IRB)&#xD;
&#xD;
          -  Patients with underlying lung disease must be judged (by the principal investigator)&#xD;
             able to with stand mucous/debris formation at the site of treatment&#xD;
&#xD;
          -  Definition of CIS or microinvasive lung cancer for this protocol: the lesion will be&#xD;
             radiographically occult and not definable by conventional computed tomography (CT) of&#xD;
             the chest; the lesion may or may not be invisible on white light bronchoscopy, but is&#xD;
             definable and photographable on lung imaging fluorescence endoscope (LIFE)&#xD;
             bronchoscopy; biopsies of the lesion must indicate no evidence of invasion beyond&#xD;
             cartilage on histopathology; the lesion may, however, be invasive through the basement&#xD;
             membrane (microinvasive carcinoma)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Porphyria or hypersensitivity to porphyrin or porphyrin-like compounds&#xD;
&#xD;
          -  White blood cells (WBC) &lt; 4000&#xD;
&#xD;
          -  Platelet count &lt; 100,000&#xD;
&#xD;
          -  Prothrombin time exceeding 1.5 times the upper normal limit&#xD;
&#xD;
          -  Total serum bilirubin &gt; 3.0 mg/dl&#xD;
&#xD;
          -  Serum creatinine &gt; 3.0 mg/dl&#xD;
&#xD;
          -  Alkaline phosphatase (hepatic) or serum glutamic oxaloacetic transaminase (SGOT) &gt; 3&#xD;
             times the upper normal limit&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease (COPD) that would in the opinion of the&#xD;
             investigator preclude multiple bronchoscopies or partial central airway obstruction&#xD;
             from mucous/debris formation&#xD;
&#xD;
          -  Any evidence of worsening pulmonary symptoms or COPD exacerbation&#xD;
&#xD;
          -  Evidence of major pulmonary vessel encasement on CT scan of the chest&#xD;
&#xD;
          -  Myocardial infarction (Ml) or unstable angina in the previous 6 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samjot Dhillon</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>August 16, 2012</study_first_submitted>
  <study_first_submitted_qc>August 17, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2012</study_first_posted>
  <last_update_submitted>July 30, 2014</last_update_submitted>
  <last_update_submitted_qc>July 30, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 31, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

